The healthcare sector is one of the most dynamic investment fields at the moment. This is actually due to a number of factors, ones that offer both an opportunity and a caution for investors. The U.S. population is rising due to longevity and … [Read more...]
S&P 500 Eases Off Share Buybacks: What Does This Mean for SPDR S&P 500 ETF Trust (SPY)
Companies belonging to the S&P 500 are easing off buyback purchases. This oddity offers a few reasons for concern, though positive outcomes are not unlikely either. So, what is going on with S&P 500 stocks and what can investors expect from … [Read more...]
Valeant Pharmaceuticals (VRX) Makes Monster Profits From Early 2017 Disposals
Forging into 2017, analysts continue to cite Valeant Pharmaceutical Intl. Inc.’s debt, public image and reduced influence among its biggest challenges. The drug maker is now set on regaining portions of the confidence it lost during the last two … [Read more...]
Pfizer Inc. (PFE) Deepens its Penetration in the EU
Pfizer Inc. has been working to acquire greater market share in multiple therapeutic areas. In an attempt to gain market share of various therapeutic areas, Pfizer Inc. is undergoing the process of developing multiple molecules. In a similar … [Read more...]
Pfizer Inc. (PFE) to Seek More Modern Headquarters in Manhattan
Pfizer Inc. World Headquarters are located where plenty of people pass by. The building lies in the Manhattan borough of New York. The largest U.S. drugmaker said yesterday that it aims to sell its world headquarters buildings in midtown Manhattan. … [Read more...]
Valeant Pharmaceuticals Intl Inc (VRX): Hedge Fund Giants Still Believe
Valeant Pharmaceuticals Intl Inc shares were the subject of a quick and staggering plummet over the last year. The company had been trading at over $250 in August 2015 and is now seen struggling to keep its mid-twenties share value afloat. Share … [Read more...]
Pfizer Inc. (NYSE:PFE) Buys BIND’s Assets
Pfizer Inc. shareholders can expect to get a 25% return from the deal with BIND. The latter has gone bankrupt and has no operations remaining. Hence, it is liquidating. This is unlike the deal with Medivation, where analysts are not entirely sure … [Read more...]
Apple Inc. (AAPL) Quitely Building Health Data Empire, Acquires Gliimpse
Apple Inc. has acquired Silicon Valley-based Gliimpse, a personal health data startup. The move, reported by Fast Company, was made earlier this year by the U.S. tech giant to boost its presence in digital health. Financial terms of the deal were … [Read more...]
Pfizer Inc. (PFE) Acquires Medivation Inc. For $14 Billion
Pfizer Inc. may on Monday announce the successful acquisition of Medivation Inc. for $14 billion, if all goes well as private indications have shown, Bloomberg reports. Although everything is still under wraps at the moment, internal sources reveal … [Read more...]
FDA Approves ‘Weed’ Drug – Insys Therapeutics (INSY) Value Flies
A “weed” drug sent the shares of Insys Therapeutics Inc. flying this Tuesday morning. INSY stock was up just over 23 percent during pre-trading. The stock spiked in the wake of a recent approval by the Food and Drug Association (FDA). The FDA just … [Read more...]